Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2015

01-02-2015 | Letter to the editor

Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders

Authors: Andrea Tendas, Maria Felicita Lissia, Daniela Piccioni, Liliana Tirimbelli, Laura Scaramucci, Marco Giovannini, Teresa Dentamaro, Alessio Perrotti, Paolo de Fabritiis, Pasquale Niscola

Published in: Supportive Care in Cancer | Issue 2/2015

Login to get access

Excerpt

To the Editor, …
Literature
1.
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF (2011) Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117(12):2697–2702PubMedCentralPubMedCrossRef
2.
Breccia M, Voso MT, Maurillo L, Niscola P, Fianchi L, Aloe Spiriti MA, Buccisano F, Latagliata R, Pelliccia S, Fenu S, Tendas A, Alimena G (2014) Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Am J Hematol 89(5):565
3.
Tendas A, Cupelli L, Siniscalchi A, Scaramucci L, Giovannini M, Dentamaro T, Perrotti AP, Caravita T, de Fabritiis P, Niscola P (2014) Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Meditter J Hematol Infect Dis 6(1):e2014020CrossRef
4.
Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76(3):218–227PubMedCentralPubMedCrossRef
5.
Niscola P, Palombi M, Trawinska MM, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P (2013) Managing myelodysplastic syndromes in very old patients: a teaching case report. Clin Interv Aging 8:391–394PubMedCentralPubMedCrossRef
6.
Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27(11):1850–1856PubMedCrossRef
7.
Voso MT, Fianchi L, Criscuolo M, Greco M, D’Alo F, Hohaus S, Pagano L, Leone G (2012) Azacitidine in a patient with myelodysplastic syndrome: impact of switching from a 5-day to the approved 7-day dosing schedule. Leuk Res 36(1):e15–e17PubMedCrossRef
8.
Pierdomenico F, Esteves S, Almeida A (2013) Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Ann Hematol 92(9):1201–1206PubMedCrossRef
9.
Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C, Bari A, Musto P, Zambello R, Fianchi L, Alimena G, Leone G (2013) Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 90(4):345–348PubMedCrossRef
10.
Niscola P, Tendas A, Giovannini M, Cupelli L, Trawinska MM, Palombi M, Scaramucci L, Brunetti GA, Perrotti A, Neri B, Efficace F, Cartoni C, de Fabritiis P, Mandelli F (2012) Transfusions at home in patients with myelodysplastic syndromes. Leuk Res 36(6):684–688PubMedCrossRef
Metadata
Title
Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders
Authors
Andrea Tendas
Maria Felicita Lissia
Daniela Piccioni
Liliana Tirimbelli
Laura Scaramucci
Marco Giovannini
Teresa Dentamaro
Alessio Perrotti
Paolo de Fabritiis
Pasquale Niscola
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2502-y

Other articles of this Issue 2/2015

Supportive Care in Cancer 2/2015 Go to the issue

Review Article

The prophylactic use of Chinese herbal medicine for chemotherapy-induced leucopenia in oncology patients: a systematic review and meta-analysis of randomized clinical trials

Original Article

Exploring the myths of morphine in cancer: views of the general practice population

Original Article

Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis

Review Article

Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review

Original Article

Reproductive health and endocrine disruption in women with breast cancer: a pilot study

ACKNOWLEDGMENT

Acknowledgment of Reviewers 2014
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits